Literature DB >> 19638480

Beyond parity: association of ovarian cancer with length of gestation and offspring characteristics.

Susan J Jordan1, Adèle C Green, Christina M Nagle, Catherine M Olsen, David C Whiteman, Penelope M Webb.   

Abstract

Women with higher parity have a lower risk of ovarian cancer possibly because of pregnancy hormones, but the specific effect of different pregnancy hormones on ovarian cancer risk is not clear. Some clarification might be gained by considering situations where hormone levels vary between pregnancies. Study participants from an Australian population-based, case-control study of epithelial ovarian cancer (2001-2005) completed a reproductive/lifestyle questionnaire. The authors included 1,203 cases and 1,286 controls with at least 1 birth and, using multiple logistic regression, calculated odds ratios and 95% confidence intervals to investigate the effects of pregnancy-related factors on cancer risk. Women who had 1 or more preterm births had higher risks of ovarian cancer than those who had only full-term births (odds ratio (OR) = 1.48, 95% confidence interval (CI): 1.02, 2.15). The authors also found that bearing only boys was associated with a 2-fold increased risk of mucinous ovarian cancer (OR = 2.19, 95% CI: 1.15, 4.17). There was no association between multiple pregnancy and ovarian cancer (for any multiple pregnancy vs. only singleton pregnancies: OR = 1.22, 95% CI: 0.74, 2.02). The results suggest that pregnancies associated with differing hormonal milieux have different effects on ovarian cancer risk and that some of these associations may vary with histologic subtype.

Entities:  

Mesh:

Year:  2009        PMID: 19638480     DOI: 10.1093/aje/kwp185

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  7 in total

1.  Preterm delivery is associated with an increased risk of epithelial ovarian cancer among parous women.

Authors:  Camilla Sköld; Tone Bjørge; Anders Ekbom; Anders Engeland; Mika Gissler; Tom Grotmol; Laura Madanat-Harjuoja; Anne Gulbech Ording; Olof Stephansson; Britton Trabert; Steinar Tretli; Rebecca Troisi; Henrik Toft Sørensen; Ingrid Glimelius
Journal:  Int J Cancer       Date:  2018-07-10       Impact factor: 7.396

2.  Use of fertility drugs and risk of ovarian cancer: results from a U.S.-based case-control study.

Authors:  Michelle L Kurta; Kirsten B Moysich; Joel L Weissfeld; Ada O Youk; Clareann H Bunker; Robert P Edwards; Francesmary Modugno; Roberta B Ness; Brenda Diergaarde
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-15       Impact factor: 4.254

3.  Offspring sex and risk of epithelial ovarian cancer: a multinational pooled analysis of 12 case-control studies.

Authors:  Francesmary Modugno; Zhuxuan Fu; Susan J Jordan; Aocs Group; Jenny Chang-Claude; Renée T Fortner; Marc T Goodman; Kirsten B Moysich; Joellen M Schildkraut; Andrew Berchuck; Elisa V Bandera; Bo Qin; Rebecca Sutphen; John R McLaughlin; Usha Menon; Susan J Ramus; Simon A Gayther; Aleksandra Gentry-Maharaj; Chloe Karpinskyj; Celeste L Pearce; Anna H Wu; Harvey A Risch; Penelope M Webb
Journal:  Eur J Epidemiol       Date:  2020-09-21       Impact factor: 8.082

4.  Gender of offspring and risk of ovarian cancer: The HOPE study.

Authors:  Zhuxuan Fu; Kirsten Moysich; Roberta B Ness; Francesmary Modugno
Journal:  Cancer Epidemiol       Date:  2019-12-10       Impact factor: 2.984

Review 5.  The role of pregnancy, perinatal factors and hormones in maternal cancer risk: a review of the evidence.

Authors:  R Troisi; T Bjørge; M Gissler; T Grotmol; C M Kitahara; S M Myrtveit Saether; A G Ording; C Sköld; H T Sørensen; B Trabert; I Glimelius
Journal:  J Intern Med       Date:  2018-03-25       Impact factor: 8.989

6.  Complications of Pregnancy and the Risk of Developing Endometrial or Ovarian Cancer: A Case-Control Study.

Authors:  Yang Liu; Xingyu Chen; Jiayi Sheng; Xinyi Sun; George Qiaoqi Chen; Min Zhao; Qi Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-30       Impact factor: 5.555

7.  Is the positivity of estrogen receptor or progesterone receptor different between type 1 and type 2 endometrial cancer?

Authors:  Fang Shen; Yifei Gao; Jingxin Ding; Qi Chen
Journal:  Oncotarget       Date:  2017-01-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.